1.Current status of liver diseases in Korea: Hepatocellular carcinoma.
The Korean Journal of Hepatology 2009;15(Suppl 6):S50-S59
Primary liver cancer, most of which is hepatocellular carcinoma (HCC), is the third common leading cancer in Korea. During the last two decades, the incidence rate of primary liver cancer has shown a modest decrease, but its mortality rate has slightly increased. The incidence of HCC, according to age, peaks in the late sixth decade in men and in the early seventh decade in women. Hepatitis B virus (HBV) is the most important risk factor, which represents approximately 70% of all HCC, and hepatitis C virus (HCV) and alcohol are the next in order of major risk factors for the development of HCC in Korea. HBV-associated HCC occurs 10 years earlier than HCV-associated HCC due to a more prolonged exposure to HBV, which is vertically transmitted almost from HBsAg-positive mother in HBV-endemic area. National Cancer Control Institute, which was reorganized in 2005, is now working for several national projects such as National Cancer Registration Program, National R&D Program for Cancer Control and National Cancer Screening Program. International collaboration for the clinico-epidemiologic research would be needed to provide the specific measures for managing HCC in diverse etiologic situations. Finally, the mechanisms of hepatitis virus-associated hepatocellular carcinogenesis might be clarified to provide insights into the advanced therapeutic and preventive approaches for HCC in Korea, where the majority of HCC originate from chronic HBV and HCV infections.
*Carcinoma, Hepatocellular/diagnosis/epidemiology/etiology/therapy
;
Humans
;
Incidence
;
Korea/epidemiology
;
*Liver Neoplasms/diagnosis/epidemiology/etiology/therapy
2.Current status of liver diseases in Korea: Hepatocellular carcinoma.
The Korean Journal of Hepatology 2009;15(Suppl 6):S50-S59
Primary liver cancer, most of which is hepatocellular carcinoma (HCC), is the third common leading cancer in Korea. During the last two decades, the incidence rate of primary liver cancer has shown a modest decrease, but its mortality rate has slightly increased. The incidence of HCC, according to age, peaks in the late sixth decade in men and in the early seventh decade in women. Hepatitis B virus (HBV) is the most important risk factor, which represents approximately 70% of all HCC, and hepatitis C virus (HCV) and alcohol are the next in order of major risk factors for the development of HCC in Korea. HBV-associated HCC occurs 10 years earlier than HCV-associated HCC due to a more prolonged exposure to HBV, which is vertically transmitted almost from HBsAg-positive mother in HBV-endemic area. National Cancer Control Institute, which was reorganized in 2005, is now working for several national projects such as National Cancer Registration Program, National R&D Program for Cancer Control and National Cancer Screening Program. International collaboration for the clinico-epidemiologic research would be needed to provide the specific measures for managing HCC in diverse etiologic situations. Finally, the mechanisms of hepatitis virus-associated hepatocellular carcinogenesis might be clarified to provide insights into the advanced therapeutic and preventive approaches for HCC in Korea, where the majority of HCC originate from chronic HBV and HCV infections.
*Carcinoma, Hepatocellular/diagnosis/epidemiology/etiology/therapy
;
Humans
;
Incidence
;
Korea/epidemiology
;
*Liver Neoplasms/diagnosis/epidemiology/etiology/therapy
4.Liver Transplantation for Hepatocellular Carcinoma.
The Korean Journal of Hepatology 2006;12(4):493-506
Since the hepatocellular carcinoma (HCC) develops in cirrhotic liver and is often multicentric, liver transplantation (LT) seems to be a rational approach for the treatment of HCC. Current selection criteria of LT for HCC are Milan criteria (single nodule < or = 5 cm , or < or = 3 nodules and
5.A clinical study of treatments on 52 patients with hepatitis B virus-associated precancerous stage hepatocellular carcinoma.
Guang-dong TONG ; Xi ZHANG ; Da-qiao ZHOU ; Jin-song HE ; Chun-ling XIAO ; Xin-liang LIU ; Ying-jun ZHENG ; Hai-hong TANG
Chinese Journal of Hepatology 2008;16(10):781-782
Adult
;
Aged
;
Carcinoma, Hepatocellular
;
etiology
;
pathology
;
prevention & control
;
therapy
;
Female
;
Hepatitis B
;
pathology
;
therapy
;
Humans
;
Male
;
Middle Aged
;
Phyllanthus
;
Phytotherapy
;
Precancerous Conditions
;
etiology
;
pathology
;
prevention & control
;
therapy
6.The Clinical Report of 1,078 Cases of Hepatocellular Carcinomas: National Cancer Center Experience.
Jae Hee CHEON ; Joong Won PARK ; Kyung Woo PARK ; Young Il KIM ; Sung Hoon KIM ; Woo Jin LEE ; Hong Suk PARK ; Sang Jae PARK ; Eun Kyoung HONG ; Chang Min KIM
The Korean Journal of Hepatology 2004;10(4):288-297
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is the third leading cause of cancer and the 5 year survival rate is 9.6% in Korea. To develop a strategy for surveillance and treatments, we studied the recent clinical characteristics of HCC diagnosed at single institution in Korea, where is in an endemic area of chronic hepatitis B. METHODS: One thousand and seventy eight patients with HCC who visited the National Cancer Center between June 2001 and December 2003 were retrospectively studied. RESULTS: The male/female ratio was 4.5:1. The mean age of the patients was 56.3 years. 74.2% of patient had hepatitis B virus (HBV) infections, 8.6% had hepatitis C virus (HCV) infections, 6.9% of the patients abused alcohol and 10.3% of the patients had non-B non-C considered as the etiologic factors of their HCC. Only 10.0% of patients had a tumor sized 2 cm or less and 53.3% of patients had a large tumor over 5 cm in diameter. 33.2% of patients had a single tumor. At the time of diagnosis, the modified UICC staging was as follows: 6.5%, 20.1%, 30.9%, 25.2% and 17.3% in stages I, II, III, IVa and IVb, respectively. The initial treatment performed was transcatheter arterial chemoembolization (48.2%), radiofrequency ablation (1.5%), hepatic resection (11.2%), systemic chemotherapy (7.5%), radiotherapy (2.1%), and conservative medical treatments (29.5%). The mean number of treatments was 1.65. The response rates to the initial treatments were 27.9% (complete response), 23.6% (partial response), 7.5% (minimal response), 14.2% (stable disease), and 30.4% (progressive disease). CONCLUSIONS: HBV infection is a major etiologic factor for Korean HCC patients. Most cases are still in advanced stages and these cases responded poorly to any treatments. The national surveillance program and its guideline for HCC are expected to improve the survival of HCC patients.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Hepatocellular/*diagnosis/etiology/therapy
;
English Abstract
;
Female
;
Humans
;
Korea
;
Liver Neoplasms/*diagnosis/etiology/therapy
;
Male
;
Middle Aged
7.Successful Treatment of Stereotactic Body Radiation Therapy Combined with Transarterial Chemolipiodolization for Hepatocellular Carcinoma with Biliary Obstruction.
Chan Kwon PARK ; Si Hyun BAE ; Hong Jun YANG ; Ho Jong CHUN ; Il Bong CHOI ; Jong Young CHOI ; Seung Kew YOON
The Korean Journal of Internal Medicine 2011;26(1):94-98
Conventional radiation therapy (RT) is a widely recognized treatment for hepatocellular carcinoma (HCC). However, conventional RT plays only a limited role in HCC treatment because of its low efficacy and the low tolerance of the liver for this modality. Stereotactic body radiation therapy (SBRT) was recently developed and represents the most advanced radiation therapy technique currently available. It can deliver a high dose in a short time to well-defined hepatic tumors, with rapid dose fall-off gradients. We believe that SBRT with transarterial chemolipiodolization (TACL) may prove promising as a combined treatment modality for HCC due to its precision and relative safety. Here we present a case of successful treatment of advanced HCC with obstructive jaundice using this combined modality.
Carcinoma, Hepatocellular/complications/*therapy
;
*Chemoembolization, Therapeutic
;
Combined Modality Therapy
;
Humans
;
Jaundice, Obstructive/etiology/therapy
;
Liver Neoplasms/complications/*therapy
;
Male
;
Middle Aged
;
*Radiosurgery
8.Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment.
Chinese Journal of Hepatology 2022;30(1):103-106
Hepatitis C virus (HCV) RNA can be cleared from the blood circulation by direct antiviral treatment to achieve sustained virologic response (SVR). Studies have shown that SVR after direct antiviral therapy can reduce the incidence of hepatocellular carcinoma; however, monitoring for hepatocellular carcinoma is still needed. This review briefly summarizes and discusses the existing studies on the possible causes of hepatitis C secondary to HCC after antiviral therapy, which is mainly divided into epigenetic alterations and abnormal DNA methylation, HCV-related cirrhosis and abnormal DNA amplification, HBV reactivation, several aspects of occult HCV infection, and the effect of direct antiviral treatment on hepatocellular carcinoma recurrence. In few cases, direct antiviral treatment cannot completely prevent the occurrence and recurrence of hepatitis C-related hepatocellular carcinoma. Therefore, its mechanism needs to be studied and explored, and clinicians should also approach it with caution.
Antiviral Agents/therapeutic use*
;
Carcinoma, Hepatocellular/drug therapy*
;
Hepatitis C/drug therapy*
;
Hepatitis C, Chronic/drug therapy*
;
Humans
;
Liver Neoplasms/etiology*
;
Sustained Virologic Response
9.Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence.
Qiang YAN ; Jun NI ; Guo-lei ZHANG ; Xing YAO ; Wen-bin YUAN ; Lin ZHOU ; Shu-sen ZHENG
Chinese Medical Journal 2013;126(5):855-859
BACKGROUNDRecurrence of hepatitis B-related hepatocellular carcinoma (HCC) after curative resection is the leading factor influencing the prognosis of the disease. Therefore, further improvement of long-term survival may depend on the prevention and treatment of the recurrent tumor. The aim of this research was to investigate the role of antiviral therapy and postoperative transcatheter arterial chemoembolization (TACE) in the prevention and treatment of hepatitis B-related HCC recurrence.
METHODSOne hundred and twenty patients who underwent curative resection of hepatitis B-related HCC between January 2005 and June 2008 at our hospital were enrolled. Patients were divided into four groups according to the post-operative adjuvant therapy they received, i.e., control, antiviral therapy group, TACE group, and combined group. The disease-free survival (DFS) and the 12-, 24-, 36-month cumulative recurrence rates were studied.
RESULTSThere was no significant difference between isolated postoperative antiviral therapy group and control in terms of disease-free survival (P = 0.283), while it was significantly higher in the TACE group compared to control (P = 0.019). In all patients, however, viral prophylactic therapy combined with/without TACE brought a favorable result compared to those only with/without TACE (P < 0.001). Similarly, no matter combined with or without antiviral treatment, postoperative TACE prolonged DFS (P = 0.015). Naturally, a combination of viral prophylactic therapy on the baseline TACE significantly benefited patients' postoperative DFS (P = 0.047) and vice verse (P = 0.002). The 24-month cumulative recurrence rates of combined group were significantly lower than that of isolated control group and antiviral therapy (P < 0.001 and P = 0.011 respectively). However, 36-month recurrence rate was significantly different in the control group compared to the TACE group and combined group (P = 0.040 and 0.002 respectively); same as the antiviral group compared to the combined group (P = 0.034).
CONCLUSIONSPost-operative TACE prevents early recurrence while antiviral therapy prevents late recurrence of HCC. Combination of antiviral therapy and TACE are suggested for prevention in HCC patients with high risk of recurrence.
Adult ; Aged ; Antiviral Agents ; therapeutic use ; Carcinoma, Hepatocellular ; drug therapy ; etiology ; therapy ; Chemoembolization, Therapeutic ; methods ; Female ; Hepatitis B ; complications ; drug therapy ; therapy ; Humans ; Liver Neoplasms ; drug therapy ; etiology ; therapy ; Male ; Middle Aged
10.A Case of Hepaticoduodenal Fistula Development after Transarterial Chemoembolization in Patient with Hepatocellular Carcinoma.
Yoon Hea PARK ; Se Hun KANG ; Seung Up KIM ; Do Young KIM ; Jun Yong PARK ; Sang Hoon AHN ; Kwang Hyub HAN ; Chae Yoon CHON
The Korean Journal of Gastroenterology 2011;58(3):149-152
Transarterial chemoembolization (TACE) is recommended as one of the first line therapy for unresectable hepatocellular carcinoma (HCC). Rupture of HCC following TACE is a rare and potentially fatal complication. We report a case of hepaticoduodenal fistula with ruptured HCC and liver abscess complicated by TACE. A 52-year-old male was treated by TACE three times, followed by radiation therapy and systemic chemotherapy. 30 days after the last TACE, right upper quadrant pain of abdomen was developed. About 1 month later, computed tomography of abdomen showed ruptured HCC with debris containing liver abscess and hepaticoduodenal fistula. Esophagogastroduodenoscopy revealed hepaticoduodenal fistula and hepatic parenchyme covered with exudate. The patient was managed with supportive care, but the hepaticoduodenal fistula persisted.
Carcinoma, Hepatocellular/radiotherapy/*therapy
;
Chemoembolization, Therapeutic/*adverse effects
;
Endoscopy, Digestive System
;
Gastric Fistula/*etiology
;
Humans
;
Liver Abscess/etiology
;
Liver Diseases/*etiology
;
Liver Neoplasms/radiotherapy/*therapy
;
Male
;
Middle Aged
;
Rupture, Spontaneous/etiology
;
Tomography, X-Ray Computed